Blueprint Medicines
BPMC
£95.84
Share price
-0.02%
Change (1 day)
5.67%
Change (1 year)
Categories
Blueprint Medicines (BPMC) - Total debt
Total debt on the balance sheet as of March 2025 : £0.34 Billion
According to Blueprint Medicines 's latest financial reports the company's total debt is £0.34 Billion. A company’s total debt is the sum of all current and non-current debts.
Blueprint Medicines - Total debt on balance sheet (from 2014 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | £0.37 B | 43.23% |
| 2023-12-31 | £0.26 B | 30.23% |
| 2022-12-31 | £0.20 B | 142.81% |
| 2021-12-31 | £82.53 M | 25.55% |
| 2020-12-31 | £65.73 M | -10.16% |
| 2019-12-31 | £73.17 M | 535.42% |
| 2018-12-31 | £11.51 M | -12.81% |
| 2017-12-31 | £13.2 M | 119.06% |
| 2016-12-31 | £6.02 M | -20.84% |
| 2015-12-31 | £7.61 M | 31.13% |
| 2014-12-31 | £5.8 M | 234.61% |
| 2013-12-31 | £1.73 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Isoray
ISR | £0.29 M | -99.92% | 🇺🇸 USA |
 OPKO Health
OPK | £0.36 B | 5.61% | 🇺🇸 USA |
 Pacific Biosciences
PACB | £0.51 B | 49.80% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |